TLX vs VKTX: Which Stock Is the Better Buy?
Telix Pharmaceuticals Limited and Viking Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — TLX vs VKTX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Telix Pharmaceuticals Limited (TLX) | Viking Therapeutics, Inc. (VKTX) | |
|---|---|---|
| Market cap | $3.2B | $3.2B |
| Revenue (latest FY) | $803.79M | $0 |
| Net income (latest FY) | $-7.13M | $-359.64M |
| Revenue growth (5y CAGR) | 94.7% | — |
| Net margin | -0.9% | — |
| Return on equity | -1.7% | -56.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | — | — |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full TLX vs VKTX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open TLX's full financials → Open VKTX's full financials →More comparisons
Frequently asked questions
Which is bigger, TLX or VKTX?
Viking Therapeutics, Inc. is larger by market capitalization — $3.2B versus $3.2B.
Which grows faster, TLX or VKTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
TLX fundamentals → · VKTX fundamentals → · All 1,500+ companies → · Free screener →